期刊文献+

BRAF、NRAS癌基因与恶性黑素瘤的研究 被引量:3

BRAF and NRAS oncogenes and malignant melanoma
原文传递
导出
摘要 近年来,世界范围内黑素瘤的发生率正逐渐升高,发病年龄也愈来愈早,其死亡率也随之增加。环境因素和遗传易感因素是恶性黑素瘤发病的主要机制。遗传易感性的研究发现,与散发性恶性黑素瘤发病密切相关的两个遗传易感基因是位于RAS.RAF—MEK.ERK途径的BRAF、NRAS基因。其中BRAF基因是黑素瘤中突变率最高的基因,也是目前黑素瘤特异性靶向治疗研究的热点基因。概述BRAF、NRAS基因突变在恶性黑素瘤形成、发生、发展中所起的重要作用,并评述BRAF基因突变在黑素瘤临床诊治上的应用价值。 Recently, there has been a gradual rise in the incidence and mortality of melanoma, and the age at onset of melanoma has tended to be younger. Environmental and genetic susceptibility factors compose the major mechanisms of malignant melanoma. Studies have shown that BRAF and NRAS genes in the RAS- RAF-MEK-ERK pathway are closely associated with the pathogenesis of sporadic malignant melanoma. BRAF appears to be the most frequently mutated gene in melanoma, and is also a resea,'ch focus in the specific targeted therapy of melanoma. This paper describes the important roles of BRAF and NRAS mutations in the formation, occurrence and development of melanoma, as well as the value of BRAF mutation in the diagnosis and treatment of melanoma.
作者 郭芳 康晓静
出处 《国际皮肤性病学杂志》 2012年第1期48-50,共3页 International Journal of Dermatology and Venereology
关键词 黑色素瘤 原癌基因蛋白质B-raf NRAS 突变 Melanoma Proto-oncogene proteins B-raf NRAS Mutation
  • 相关文献

参考文献18

  • 1Daniotti M, Ferrari A, Frigerio S, et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol, 2009, 129(7): 1759-1768.
  • 2Rager EL, Bridgeford EP, Ollila DW. Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment. Am Faro Physician, 2005, 72(2): 269-276.
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin, 2008,56(2):71-96.
  • 4Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg, 2007, 60 (1): 32-40.
  • 5Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
  • 6Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res, 2002, 62 (23): 6997-7000.
  • 7Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol, 2010, 22 (3): 178- 183.
  • 8Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS, 2007, 115 ( 10): 1161-1176.
  • 9Bloethner S, Scherer D, Drechsel M, et al. Malignant melanoma-- a genetic overview. Actas Dermosifiliogr, 2009, 100 (Suppl 1 ): 38-51.
  • 10Jovanovie B, Egyhazi S, Eskandarpour M, et al. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol, 2010, 130(2): 618-920.

二级参考文献23

  • 1Middleton MR, Grob J J, Aaronson N, et al. Randomized phase Ⅲ study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [J]. J Clin Oncol,2000,18 ( 1 ) : 158 - 166.
  • 2Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase Ⅱ study [ J ]. J Clin Oncol,2004,22( 11 ) : 2101 -2107.
  • 3Avril MF, Aamdal S, Grob J J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase Ⅲ study [J]. J Clin Oncol,2004,22 (6) :1118 -1125.
  • 4Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma [ J ]. Curr Opin Immunol,2009,21 (2) :233 -240.
  • 5McDermott DF, Sosman JA, Gonzalez R, et al. Doubleblind randomized phase Ⅱ study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group [J]. J Clin Oncol,2008,26(13) :2178 -2185.
  • 6Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase Ⅲ, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage Ⅲ or stage Ⅳ melanoma [ J ]. J Clin Oncol, 2009,27 (17) :2823 -2830.
  • 7Amaravadi R, Schuchter LM, McDermott DF. Updated results of a randomized phase Ⅱ study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma [J]. J Clin Oncol, 2007,25 (18S) :8527.
  • 8Munzone E,Testori A,Minchella I,et al. A phase Ⅱ trail of daearbazine(DTIC) and bevaeizumab in patients with metastatic melanoma [J]. J Clin Oneol,2007,25 (18S): 8579.
  • 9Munzone E,Testori A,Minchella I,et al. Phase Ⅱ trail of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage Ⅳ melanoma [ J ]. J Clin Oncol,2007,25(18S) :8560.
  • 10Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz- Schmidt KU, Szurman P. Suppression of melanoma- associated neoangiogenesis by bevacizumab [J]. Arch Dermatol,2008,144(4) :525 - 527.

共引文献25

同被引文献36

  • 1Hodi FS, CKDay SJ, McDermott DF, et al. Improved survival withipilimumab in patients with metastatic melanoma. N Engl J Med,2010,363(8): 711-723.
  • 2Kong Y, Si L, Guo J, et al. Aberrations of KIT, BRAF, NRAS, andPDGFRA in Chinese melanoma patients and their significance:Large, scale analysis of 644 patients. J Clin Oncol, 2011, 29(15): 8568.
  • 3Ellerhorst JA, Greene VR,Ekmekcioglu S,et al. Clinical corre-lates of NRAS and BRAF mutations in primary humanmelanoma. Clin Cancer Res, 2011, 17(2): 229-235.
  • 4Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF genein human cancer. Nature, 2002, 417(6892): 949-954.
  • 5Brose MS, Volpe P,Feldman M, et al. BRAF and RAS mutationsin human lung cancer and melanoma. Cancer Res, 2002, 62(23): 6997-7000.
  • 6Goel VK, Lazar AJ, Wameke CL, et al. Examination of mutationsin BRAF, NRAS, and PTEN in primary cutaneous melanomajInvest Dermatol, 2006, 126(1): 154-160.
  • 7Dhomen N,Marais R. BRAF signaling and targeted therapies inmelanoma. Hematol Oncol Clin North Am, 2009, 23 (3): 529-545.
  • 8Uhara H, Ashida A, Koga H, et al.NRAS mutations in primary and metastatic melanomas of Japanese patients[J].Int J Clin Oncol,2013,19(3) :544-548.
  • 9Pho L, Grossman D, Leaehman SA. Melanoma genetics:a re- wiew of genetic factors and clinical phenotypes in familial mel- anoma[J].Curr Opin Oncol,2006,18(2), 173-179.
  • 10Fernandez-Medarde A, Santos E. Ras in cancer and develop- mental diseases[J].Genes Cancer, 2011,2 (3) : 344-358.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部